Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Q1 2022 vs. Q4 2021
How the institutions holding Navidea Biopharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 31 | 25 | −6 |
| Shares | 1.68M | 1.51M | −167.7K (−10.0%) |
| Value | $1.68M | $1.19M | −$487.0K (−29.0%) |
New holders (1)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Beacon Capital Management, LLC | 10 | $0 | 0.00% |
Sold out (7)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Commonwealth Equity Services, LLC | 51,203 | $51.0K |
| Two Sigma Investments, LP | 33,467 | $33.0K |
| Wolverine Trading, LLC | 12,484 | $13.0K |
| Advisor Group Holdings, Inc. | 2,150 | $2.00K |
| Northwestern Mutual Wealth Management Co | 237 | $0 |
| IFP Advisors, Inc | 50 | – |
| CoreCap Advisors, LLC | 45 | – |